July 24, 2024
To whom it may concern:

Company Name:
Corporate
Representative:
Contact:

TOHO HOLDINGS CO.,LTD.
Hiromi Edahiro, Representative Director,
CEO and CFO(Prime Market of Tokyo Stock Exchange
Securities Code: 8129)
Makoto Kawamura, Corporate Officer andGeneral Manager, Corporate Strategy Division(TEL: 81-3-6838-2803)

Announcement of Investment in Hirosaki Lifescience Innovation, Inc.
TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO and CFO: Hiromi Edahiro;
hereinafter, “TOHO HOLDINGS”) announces that it has invested in Hirosaki Lifescience Innovation, Inc.
(Headquarters: Tokyo; President and CEO: Hiroki Ishikawa; hereinafter, “Hirosaki LI”), as described below.
1. Reason for investment
TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged inpharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development
and provision of customer support systems under the corporate slogan “Total Commitment to Good Health”.
TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and homecare.
Hirosaki LI is a bio-venture established in Hirosaki City, Aomori Prefecture, with the purpose of developing,manufacturing, and selling regenerative medical products. Hirosaki LI handles excellent regenerative medicalproducts using collagen matrices such as amniotic membrane processed sheets. The company is currently engaged
in the development of an autologous chondrocyte-processed product (Development code: IK-01) for the treatmentof knee osteoarthritis using a three-dimensional collagen matrix. In addition, Hirosaki LI manufactures and sells
SAKRACY® (launched in September 2022), a regenerative medical product designed to reduce adhesion on theocular surface in patients with limbal stem cell deficiency (LSCD), and is currently working to further expand its
manufacturing capabilities.
Through this investment, TOHO HOLDINGS will support Hirosaki LI’s business development andenhancement of production capacity, and will further promote its efforts in regenerative medical products, which
are expected to grow in the future. In addition, the Group will fully cooperate with Hirosaki LI on distribution byutilizing its nationwide distribution network, sophisticated distribution system, and know-how in emergency
response.
We have been entrusted with the distribution of SAKRACY®, a regenerative medical product, since April 2024.
This product is the second regenerative medical product handled by TOHO HOLDINGS.
2. Overview of Hirosaki LI(1) Company name:(2) Location:(3) Representative:(4) Established:(5) Business content:(6) Capital:(7) Number of employees:

Hirosaki Lifescience Innovation, Inc.
9-6 Nibancho, Chiyoda-Ku, TOKYO, JAPAN.
Hiroki Ishikawa, President and CEO
September 16, 2015
Development, Manufacture and Sale of Regenerative Medical products
80 million yen20

3．Forward looking outlook
While we expect that this transaction will have only a negligible impact on consolidated earnings of TOHOHOLDINGS, we believe that it will contribute to increase the Group’s corporate value over the medium to longterm. The Company will disclose any impact promptly if it becomes necessary to do so in the future.
Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.